4D Molecular Therapeutics FDMT Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $3.05M-96.4% | $85.09M+94,444% | $90K+500% | $15K+7.1% | $14K+1,300% | ||
| $64.98M+12.8% | $57.61M+16.5% | $49.44M+3.1% | $47.95M+17.8% | $40.7M-5.5% | ||
| $11.69M-8.5% | $12.77M+7.9% | $11.84M+2.8% | $11.52M-10.9% | $12.94M-0.7% | ||
| $76.67M+8.9% | $70.38M+14.9% | $61.28M+3.0% | $59.47M+10.9% | $53.64M-4.4% | ||
| -$73.62M— | $0+100% | -$61.19M-2.9% | -$59.46M-10.9% | -$53.62M+4.4% | ||
| -2,416.1%-2,416pp | 0%+67,983pp | -67,983.3%+328,390pp | -396,373.3%-13,366pp | -383,007.1%+5,228,693pp | ||
| $4.86M+3.8% | $4.68M+8.7% | $4.31M-10.2% | $4.8M-15.1% | $5.65M-12.4% | ||
| -$68.76M— | —— | -$56.88M-4.1% | -$54.66M-13.9% | -$47.97M+3.4% | ||
| -2,256.6%— | —— | -63,195.6%+301,191pp | -364,386.7%-21,730pp | -342,657.1%+4,624,443pp | ||
| -$1.01— | —— | -$1.01-3.1% | -$0.98-14.0% | -$0.86+4.4% | ||
| -$72.35M-6,050% | $1.22M+102% | -$59.92M-2.8% | -$58.29M-10.9% | -$52.57M+4.5% | ||
| -2,374.5%-2,376pp | 1.4%+66,584pp | -66,582.2%+322,018pp | -388,600%-13,100pp | -375,500%+5,126,600pp | ||
| -$73.62M— | $0+100% | -$61.19M-2.9% | -$59.46M-10.9% | -$53.62M+4.4% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is 4D Molecular Therapeutics's revenue?
- 4D Molecular Therapeutics (FDMT) generated $88.2M in revenue over the trailing twelve months, up 383560.9% year over year.
- Is 4D Molecular Therapeutics profitable?
- 4D Molecular Therapeutics is not currently profitable: it reported a net loss of $228.3M over the trailing twelve months, a -174314.2% net margin.
- What is 4D Molecular Therapeutics's earnings per share?
- 4D Molecular Therapeutics's diluted EPS over the trailing twelve months is $-3.86.
- Where does 4D Molecular Therapeutics's income statement data come from?
- Every line is extracted from 4D Molecular Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
